Why Wave Life Sciences Stock Vaulted 146% Higher on Monday

Why Wave Life Sciences Stock Vaulted 146% Higher on Monday

Key PointsThe biotech's investigational weight loss drug did very well in a clinical trial.This is a white-hot segment of the pharmaceutical market, so it's little wonder investors subsequently pounced on the stock.10 stocks we like better than Wave Life Sciences › Even in the volatile biotech sector, it's rare for a company's stock price to more than double in a single trading session. This is what made Monday so memorable for Wave Life Science…

Updated: Wave Life Sciences’ RNA obesity shot cuts fat and retains muscle, but appears to lag Lilly’s

Wave Life Sciences’ obesity therapy helped patients lose more fat mass and retain more muscle than low doses of Novo Nordisk’s Wegovy or Eli Lilly’s muscle-sparing candidate bimagrumab when compared across different clinical trials. ...

Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025

December 07, 2025 16:00 ET  | Source: Wave Life Sciences USA, Inc. CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will announce interim data from the ongoing Phase 1 INLIGHT clinical trial […] The post Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WV…

Wave Life Sciences (Nasdaq: WVE) to share WVE-007 INLIGHT Phase 1 obesity data, host call

Wave Life Sciences will release interim data from its Phase 1 INLIGHT trial of WVE-007 for obesity on Dec. 8 at 7:30 a.m. ET, followed by an 8:30 a.m. investor call.